Company profile: Cellinfinity Bio
1.1 - Company Overview
Company description
- Provider of a machine-learning-driven genome editing platform and engineered cell therapies. Offers CLASH to enable precise, replicable site-specific edits across up to 20,000 genes to discover enhancements for cell therapy; HYPERBOOSTS (gain-of-function) and ENDOMODS (loss-of-function) genes; OPTI-CARS CAR design optimizations; and Supercharged Cell Therapy CAR-T and CAR-NK cells enhanced for potency, persistence, penetration, and memory against solid tumors.
Products and services
- Supercharged Cell Therapy™: Custom-engineered CAR-T and CAR-NK cells programmed with multiple gene enhancements to increase potency, persistence, penetration, and memory, delivering improved efficacy against solid tumors
- CLASH™: Machine learning-driven platform that edits up to 20,000 genes with precise, replicable, site-specific changes to discover gene enhancements that advance cell therapy
- OPTI-CARS: CLASH-derived modifications to CAR design that enhance effectiveness of CAR-T and CAR-NK cells for improved cell therapy performance
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cellinfinity Bio
SmartHealth Dx
HQ: United States
Website
- Description: Provider of precision diagnostics addressing unmet clinical needs in vascular, metabolic, and oncological diseases, including SmartVascular Dx (blood test for vascular inflammation and stroke risk), SmartLung Dx (noninvasive test to identify benign lung nodules), SmartKidney Dx (metastasis risk in kidney disease), SmartScience Dx (~195,000-sample serum repository for biomarker discovery), and SmartPath Dx (real-time pathology imaging).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SmartHealth Dx company profile →
AdnaGen
HQ: Germany
Website
- Description: Provider of molecular genetic diagnostic testing systems for medical and clinical research laboratories, offering AdnaTest kits with reagents for immunomagnetic selection, mRNA isolation, and multiplex RT-PCR for tumor diagnostics, and focusing on genetic pre-disposition.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AdnaGen company profile →
Novian Health
HQ: United States
Website
- Description: Provider of proprietary interstitial laser therapy solutions for the focal destruction of breast tumors, including Novilase Breast Therapy, the Interstitial Laser System for breast-conserving procedures, and evidence-generation programs such as the ABLATE Registry and BR-003 clinical trial to support reimbursement and U.S. marketing clearance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novian Health company profile →
BioNovion
HQ: United States
Website
- Description: Provider of immune oncology antibody discovery and development focused on antibodies for the immune therapy of cancer; U.S.-based, founded in 2011 and acquired by Aduro BioTech in 2015.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioNovion company profile →
Scandinavian ChemoTech
HQ: Sweden
Website
- Description: Provider of cancer care technologies, including IQwave – TSE (Tumour Specific Electroporation), a device and method that enhances uptake of cytotoxic drugs into tumor cells via electroporation, and D-EECT (Dynamic‑ElectroEnhanced ChemoTherapy), a treatment protocol aimed at better clinical outcomes for palliative patients with large tumor burdens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scandinavian ChemoTech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cellinfinity Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cellinfinity Bio
2.2 - Growth funds investing in similar companies to Cellinfinity Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cellinfinity Bio
4.2 - Public trading comparable groups for Cellinfinity Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →